Inflammation: The Hidden Heart Disease Risk?

Cardiovascular disease, the leading cause of death in the U.S., is often poorly assessed by traditional screenings that focus solely on cholesterol and triglycerides. Emerging research highlights chronic, low-grade inflammation as a crucial, often overlooked, factor in the development of atherosclerotic cardiovascular disease. This persistent inflammation, distinct from acute responses, quietly damages blood vessels over time, even in individuals undergoing treatment for heart conditions.

The American College of Cardiology now recommends incorporating inflammatory biomarker tests into cardiovascular risk assessments. Such tests, including high-sensitivity C-reactive protein (hs-CRP) and Lipoprotein(a) (Lp(a)), are readily available and can detect risk factors that standard lipid panels miss. Elevated hs-CRP, for instance, is as predictive of future cardiac events as high LDL cholesterol in some individuals, proving inflammation's significant role.

Understanding inflammatory markers like hs-CRP, Lp(a), remnant cholesterol, and white blood cell differentials provides a more complete picture of heart health. Biomarker ratios, such as LDL-C/ApoB and triglyceride-to-HDL cholesterol, offer further insights into metabolic health and immune stress. Addressing chronic inflammation through lifestyle modifications—including regular exercise, a healthy diet, adequate sleep, and weight management—is paramount for reducing cardiovascular risk.